Acinetobacter Pneumonia Therapeutics Market to Reach USD 927.1 Million to 2031
07 mars 2024 04h50 HE
|
InsightAce Analytic Pvt. Ltd.
Jersey City, NJ, March 07, 2024 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Acinetobacter Pneumonia Therapeutics Market Size,...
ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study
16 oct. 2023 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370
18 sept. 2023 07h30 HE
|
ContraFect Corporation
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens
20 juin 2023 08h59 HE
|
ContraFect Corporation
YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
ContraFect Data Presentations at the 33rd Annual ECCMID Meeting Highlight the Potential Efficacy of Lysin CF-370 Against Antibiotic Resistant Gram-negative Pathogens
20 avr. 2023 08h30 HE
|
ContraFect Corporation
YONKERS, N.Y., April 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect Reports Third Quarter 2022 Financial Results and Provides Corporate Update
14 nov. 2022 08h00 HE
|
ContraFect Corporation
YONKERS, N.Y., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...
Entasis Therapeutics Announces Multiple Presentations at ID Week 2019
03 oct. 2019 16h01 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat...
GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea
30 sept. 2019 01h00 HE
|
Entasis Therapeutics Holdings Inc.
Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections...
Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019
27 juin 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
Entasis Therapeutics Strengthens Leadership Team with Appointment of Eric Kimble as Chief Commercial Officer
23 avr. 2019 08h00 HE
|
Entasis Therapeutics Holdings Inc.
WALTHAM, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...